This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Generic Name
- Etirinotecan pegol
- DrugBank Accession Number
- DB14951
- Background
Etirinotecan pegol is under investigation in clinical trial NCT01663012 (Phase II NKTR-102 In Bevacizumab-Resistant High Grade Glioma).
- Type
- Small Molecule
- Groups
- Investigational
- Synonyms
- Etirinotecan pegol
- External IDs
- NKTR-102
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug eventsImprove clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events & improve clinical decision support.- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareArticaine The risk or severity of methemoglobinemia can be increased when Etirinotecan pegol is combined with Articaine. Benzocaine The risk or severity of methemoglobinemia can be increased when Etirinotecan pegol is combined with Benzocaine. Benzyl alcohol The risk or severity of methemoglobinemia can be increased when Etirinotecan pegol is combined with Benzyl alcohol. Bupivacaine The risk or severity of methemoglobinemia can be increased when Etirinotecan pegol is combined with Bupivacaine. Butacaine The risk or severity of methemoglobinemia can be increased when Etirinotecan pegol is combined with Butacaine. Butamben The risk or severity of methemoglobinemia can be increased when Etirinotecan pegol is combined with Butamben. Capsaicin The risk or severity of methemoglobinemia can be increased when Etirinotecan pegol is combined with Capsaicin. Chloroprocaine The risk or severity of methemoglobinemia can be increased when Etirinotecan pegol is combined with Chloroprocaine. Cinchocaine The risk or severity of methemoglobinemia can be increased when Etirinotecan pegol is combined with Cinchocaine. Cocaine The risk or severity of methemoglobinemia can be increased when Etirinotecan pegol is combined with Cocaine. 
Identify potential medication risksEasily compare up to 40 drugs with our drug interaction checker.Get severity rating, description, and management advice.Learn more - Food Interactions
- Not Available
Categories
- ATC Codes
- L01CE03 — Etirinotecan pegol
- Drug Categories
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- LJ16641SFT
- CAS number
- 848779-32-8
- InChI Key
- Not Available
- InChI
- Not Available
- IUPAC Name
- Not Available
- SMILES
- Not Available
References
- General References
- Not Available
- External Links
- Wikipedia
- Nektar_Therapeutics
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 3 Completed Treatment Breast Cancer / Metastatic Cancer 1 3 Completed Treatment Locally Recurrent Breast Cancer / Metastatic Breast Cancer 1 2 Completed Treatment Anaplastic Astrocytoma (AA) / Anaplastic Oligodendroglioma (AO) / Glioblastoma Multiforme (GBM) 1 2 Completed Treatment Brain Metastases / Extensive-stage Small Cell Lung Cancer (SCLC) / Metastatic Breast Cancer / Recurrent Non-small Cell Lung Cancer / Recurrent Small Cell Lung Cancer (SCLC) / Stage IV Non-small Cell Lung Cancer (NSCLC) 1 2 Completed Treatment Breast Cancer / Tumor 1 2 Completed Treatment Colorectal Cancer 1 2 Completed Treatment Colorectal Cancer / Tumor 1 2 Completed Treatment Malignant Solid Neoplasms 1 2 Completed Treatment Metastatic Non-Small Cell Lung Cancer / Recurrent Non-small Cell Lung Cancer 1 2 Completed Treatment Ovarian Cancer / Tumor 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
- Not Available
- Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Not Available
Drug created at May 20, 2019 14:37 / Updated at February 21, 2021 18:55